MYCN can also be overexpressed in other tumours including medulloblastoma, retinoblastoma, small cell lung cancer, glioblastoma and other embryonal tumours [17] suggesting the implication of MYCN dosage in cancer development and aggressive expressivity. The gene discussed is MYCN; the disease is glioblastoma.